peplexicon
Choose your depth

Context, anatomy, and key evidence

← Peptide library

EPO-derived peptide

ARA-290

Published evidence · coverage incomplete
Anatomical contextAnatomy connections are not mapped yet.

No body region is highlighted until this profile has a supported anatomical connection. This does not mean the peptide has no biological effects.

Read published mechanism findings ↓

At a glance

What is it—and why does it matter?

The peptide cibinetide is identified in the review as ARA-290, indicating these names refer to the same agent in this context. Being included in a review does not imply efficacy; it only indicates the topic is covered as part of the evidence summary.

Sources for this introduction: [1] [2]

This published profile is a reference in progress. Findings retain their source context; missing topics are marked below.

What is it?

A molecule, not a product name.

Identity

The peptide cibinetide is identified in the review as ARA-290, indicating these names refer to the same agent in this context.

Sources[1]pubmedPeptides in Regenerative Medicine: A Comprehensive Review of Clinical Applications in Tissue Repair and Chronic Pain Management.This narrative review summarizes the current evidence on regenerative peptides relevant to chronic pain management, including collagen peptides, body protection compound-157 (BPC-157), thymosin beta-4 (TB-4), thymosin beta-500 (TB-500), glycyl-L-histidyl-L-lysine copper (GHK-Cu), growth hormone-related peptides, and cibinetide (ARA-290).[1]pubmedPeptides in Regenerative Medicine: A Comprehensive Review of Clinical Applications in Tissue Repair and Chronic Pain Management.cibinetide (ARA-290)
Source records
2
Independent studies
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “This narrative review summarizes the current evidence on regenerative peptides relevant to chronic pain management, including collagen peptides, body protection compound-157 (BPC-157), thymosin beta-4 (TB-4), thymosin beta-500 (TB-500), glycyl-L-histidyl-L-lysine copper (GHK-Cu), growth hormone-related peptides, and cibinetide (ARA-290).”

    Peptides in Regenerative Medicine: A Comprehensive Review of Clinical Applications in Tissue Repair and Chronic Pain Management. · PURPOSE OF REVIEW

    pubmed:42635865:c5c0752aee5b:c5c0752aee5b
  2. supports · Source-backed record
    “cibinetide (ARA-290)”

    Peptides in Regenerative Medicine: A Comprehensive Review of Clinical Applications in Tissue Repair and Chronic Pain Management. · PURPOSE OF REVIEW

    pubmed:42635865:c5c0752aee5b:c5c0752aee5b

How does it work?

Target, response, and disposition.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

What has been studied?

What the evidence says.

Study findings

Being included in a review does not imply efficacy; it only indicates the topic is covered as part of the evidence summary.

Sources[1]pubmedPeptides in Regenerative Medicine: A Comprehensive Review of Clinical Applications in Tissue Repair and Chronic Pain Management.This narrative review summarizes the current evidence on regenerative peptides relevant to chronic pain management, including collagen peptides, body protection compound-157 (BPC-157), thymosin beta-4 (TB-4), thymosin beta-500 (TB-500), glycyl-L-histidyl-L-lysine copper (GHK-Cu), growth hormone-related peptides, and cibinetide (ARA-290).
Source records
1
Independent studies
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “This narrative review summarizes the current evidence on regenerative peptides relevant to chronic pain management, including collagen peptides, body protection compound-157 (BPC-157), thymosin beta-4 (TB-4), thymosin beta-500 (TB-500), glycyl-L-histidyl-L-lysine copper (GHK-Cu), growth hormone-related peptides, and cibinetide (ARA-290).”

    Peptides in Regenerative Medicine: A Comprehensive Review of Clinical Applications in Tissue Repair and Chronic Pain Management. · PURPOSE OF REVIEW

    pubmed:42635865:c5c0752aee5b:c5c0752aee5b

Risks and interactions

Risks, organized for scanning.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

Products and regulatory status

Same ingredient. Different records.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

Administration context

The practical clinical context.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

Research status + gaps

What still needs better answers?

  • No publishable claim yet for: administration, contraindication, interaction, mechanism, regulatory, safety
  • 33 compiled claim(s) withheld by automated assurance: assurance_score_below_0.58 (19), assurance_score_below_0.72 (14), current_regulatory_source_required (7), extraction_ambiguity (4), high_risk_requires_regulatory_or_two_independent_sources (14), no_direct_support (33), proposal_not_staged (1)

These are the limits of this profile, not an exhaustive list of scientific uncertainties.

References + discovery

Open the records yourself.

  1. Peptides in Regenerative Medicine: A Comprehensive Review of Clinical Applications in Tissue Repair and Chronic Pain Management. ↗

    pubmed · published 2026-08-24 · retrieved 2026-08-25T22:43:25Z

Publication history and provenance

Version 5 · Automated assessment · 2026-08-25T22:43:25Z

b8ff97d54b3f11b5f2441acb455a585b2009afc4c934353081f401e489352526